SimkoRJ, TsungFFW, StanekEJ. Activated clotting time versus activated partial thromboplastin time for therapeutic monitoring of heparin. Ann Pharmacother1995;29:1115-21.
2.
RaschkeRA, ReillyBM, GuidryJR. FontanaJR, SrinivasS.The weight-based heparin nomogram compared with a “standard care” nomogram. Ann Intern Med1993;119:874-81.
3.
HullRD, RaskobGE, RosenbloomD, LemaireJ, PineoGF, BaylisB,. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med1992;152:1589-95.
4.
BeckerRC, CyrJ, CorraoJM, BallSP. Bedside coagulation monitoring in heparin-treated patients with active thromboembolic disease: a coronary care unit experience. Am Heart J1994;128:719-23.
5.
BowersJ, FergusonJJIII. The use of activated clotting times to monitor heparin therapy during and after interventional procedures. Clin Cardiol1994;17:357-61.
6.
ReinerJS, CoyneKS, LunderganCF, RossAM. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time. Cathet Cardiovasc Diagn1994;32:49-52.
7.
HattersleyPG, MitsuokaC, KingJH. Heparin therapy for thromboembolic disorders: a prospective evaluation of 134 cases monitored by the coagulation time. JAMA1983;250:1413-6.
8.
In: Comprehensive hematology-limited coagulation module 1986 survey, set Hl-C, Chicago: College of American Pathologists, 1986:14.
